Prominent proteins in cancer

Prominent proteins in cancer
This is the list of significantly mutated genes (SMGs) and other proteins significantly involved in edgetic perturbations in LUAD.

Perturbation type	Gene	Citation	Cancer type	Gene-disease relation
Top gains	SPECC1(Isoform switch)	18486272	LUAD	Differentially expressed in patients with lung adenocarcinoma compared to patient group lung squamous cell carcinoma
Top losses	SUPT3H (Isoform switch)	18486272	LUAD	Differentially expressed in patients with lung adenocarcinoma compared to patient group lung squamous cell carcinoma
Top losses	SUPT3H (Isoform switch)	18486272	LUAD	Differentially expressed in patients with lung adenocarcinoma compared to patient group lung squamous cell carcinoma
Top losses	USP22 (Isoform switch)	18486272	LUAD	Differentially expressed in patients with lung adenocarcinoma compared to patient group lung squamous cell carcinoma
Top gains	ABCC2	28442702	NSCLC	ABCC2 rs717620 can be used to predict the outcomes of Uygur patients with advanced NSCLC .
Top gains	AGMAT	UHOD 26(2):103-108 (ww.uhod.org)	LUAD	Increased level agmatinase in lung cancer patients comapred to heathy controls.
Top gains	CDC25C	28566436	NSCLC	Overexpression of either CDC25C lead to bypass of G2-M arrest and induced ganetespib resistance in vitro and in vivo in KRAS-mutant NSCLC.
Top gains	HPDL	23714854	SCLC	Differentially expressed in SCLC tumor samples compared to normal samples.
Top gains	KCNJ10	28219421	LUAD	Differentially expressed in side-population (SP) cells compared to non-SP celles in lung cancer cell line NCI-H460.
Top gains	NEIL3	27042257	LUAD	Differentially expressed in lung cancer cells compared to non-cancerous lung tissue sapmles.
Top gains	RGS17	19244110	LUAD	Increased expression in lung cancer samples versus normal control tissue.
Top gains	SGO1	27526110	LUAD	RAG1−/− Sgo1−/+ mice showed high incidence of lung adenocarcinoma.
Top gains	SOX30	30514297	LUAD	SOX30 is a key regulator of desmosomal gene suppressing tumor growth and metastasis in lung adenocarcinoma.
Top gains	SPC24	29029446	LUAD	A potential prognostic biomarker SPC24 promotes tumorigenesis and metastasis in lung cancer.
Top cancer-specific gains	SLC25A21	21151896	LUAD	SLC25A21 lays in a region of genomic aberrations in lung adenocarcinoma in never smokers.
Top losses	ADRA1D	26735301	SCLC	ADRA1D potentially has anti-SCLC activity and was administered to a 20 patients with stage 4 SCLC. ADRA1 administration did not result in a statistically significant OS benefit
Top losses	APOA1	27648369	LUAD	APOA1 levels were significantly lower in lung cancer patients.
Top losses	APP	29387243	LUAD	miR-373-3p promotes lung adenocarcinoma cell proliferation via APP.
Top losses	ASB14	23714854	SCLC	Differentially expressed in SCLC tumor samples compared to normal samples.
Top losses	ASB16	Greer RM Dissertation Dallas 2011	NSCLC	The expression level of ASB16 was downregulated after treatment by gemcitabine+cisplatin in Non-small-cell lung carcinoma (NSCLC) cells.
Top losses	AVPR2	11429190	NSCLC:SCLC	Overxpressed in NSCLC and SCLC.
Top losses	BEX1	24970476	NSCLC:SCLC	BEX1 was highly expressed in some NSCLC cell lines and most SCLC cell lines.
Top losses	BMX	29208667	SCLC	Etk (BMX) interacts with PFKFB4 to promote SCLC chemoresistance through regulation of autophagy.
Top losses	BTNL8	24735754	LUAD invasive	Down-regulated in invasive lung adenocarcinoma cells.
Top losses	CAV3	23714854	SCLC	Differentially expressed in SCLC tumor samples compared to normal samples.
Top losses	CCDC36	23714854	SCLC	Differentially expressed in SCLC tumor samples compared to normal samples.
Top losses	COLEC10	23714854	SCLC	Differentially expressed in SCLC tumor samples compared to normal samples.
Top losses	DNASE2B	Int J Clin Exp Med 2018;11(11):11846	NSCLC	DNASE2B serves an important role in the growth of lung cancer cells; and may be considered as a potential biomarker and therapeutic target for lung cancer.
Top losses	ENPP6	23714854	SCLC	Differentially expressed in SCLC tumor samples compared to normal samples.
Top losses	GATA1	28566697	LUAD	Down-regulated GATA-1 up-regulates interferon regulatory factor 3 in lung adenocarcinoma.
Top losses	GNMT	23714854	SCLC	Differentially expressed in SCLC tumor samples compared to normal samples.
Top losses	HSPB3	23714854	SCLC	Differentially expressed in SCLC tumor samples compared to normal samples.
Top losses	IL9R	23065014	LUAD	Both IL-9 and IL-17 substantially promoted the proliferation and migratory activity of lung cancer cells.
Top losses	INCA1	25938545:21750715	LUAD	ING5 overexpression in lung cancer A549 cells inhibited cell proliferation and invasiveness; while ING5 knockdown in lung cancer H1299 cells promoted cell aggressiveness. The inhibitor of growth protein 5 (ING5) depends on INCA1 as a co-factor for its antiproliferative effects
Top losses	L1TD1	28093071	LUAD	L1TD1 is tumor-specifically methylated in NSCLCs and that DNA methylation is involved in the transcriptional regulation of these genes.
Top losses	MYOC	23714854	SCLC	Differentially expressed in SCLC tumor samples compared to normal samples.
Top losses	OLIG1	17388669	NSCLC	OLIG1 protein expression significantly correlates with overall survival in NSCLC patients.
Top losses	PPARGC1B	22777349	NSCLC	PGC-1beta mediates adaptive chemoresistance to cisplatin associated with mitochondrial DNA mutations in non-small-cell lung cancer cells
Top losses	PTPN5	23714854	SCLC	Differentially expressed in SCLC tumor samples compared to normal samples.
Top losses	RAB40A	23714854	SCLC	Differentially expressed in SCLC tumor samples compared to normal samples.
Top losses	SH3GL2	22968441	NSCLC	SH3GL2 is frequently deleted in NSCLC and downregulates tumor growth by modulating EGFR signaling.
Top losses	SH3GL3	15087295	LUAD	Differentially expressed in lung cancer samples.
Top losses	SLC2A4	Wei C; AACR Annual Meeting 2017; Washington DC	LUAD	GLUT4 (SLC2A4) exhibits a non-canonical role of regulating lung cancer metastasis.
Top losses	TCAP	25485619	SCLC	Differentially expressed in SCLC cell lines (high-throughput experiments).
Top losses	WNT3A	29218239	NSCLC	Wnt3a expression is positively correlated with the of NSCLC patients.
Top cancer-specific losses	PPARGC1B	22777349	NSCLC	PGC-1beta mediates adaptive chemoresistance to cisplatin associated with mitochondrial DNA mutations in NSCLC.
SMGs within edgetic gains or losses	AKT1	30556874	LUAD	LINC00324 exerts tumor-promoting functions in lung adenocarcinoma via targeting miR-615-5p/AKT1 axis
SMGs within edgetic gains or losses	ARID1A	24566899	NSCLC	ARID1A is downregulated in NSCLC and regulates cell proliferation and apoptosis.
SMGs within edgetic gains or losses	BAP1	21941004	LUAD	Germline BAP1 mutation predisposes to uveal melanoma; lung adenocarcinoma; meningioma; and other cancers.
SMGs within edgetic gains or losses	CTNNB1	10070329	LUAD	Reduced beta-catenin expression in surgically treated NSCLC is clearly associated with lymph node metastasis and an infavourable prognosis.
SMGs within edgetic gains or losses	CUL3	21795997	NSCLC	Multiple component disruption of KEAP1-CUL3-RBX1 complex represents a novel mechanism of NF-κB activation in NSCLC.
SMGs within edgetic gains or losses	DROSHA	29236960	NSCLC	MicroRNA-128-3p-mediated depletion of Drosha promotes lung cancer cell migration.
SMGs within edgetic gains or losses	EGFR	28430586	NSCLC	EGFR has been identified as an oncogenic driver of NSCLC; especially activating mutations EGFR and its inhibition with specific TKIs can generate dramatic tumor responses.
SMGs within edgetic gains or losses	FGFR2	30013642	NSCLC	The expression level of FGFR2 mRNA in the NSCLC tissues was significantly higher than that in the adjacent normal tissues.
SMGs within edgetic gains or losses	KRAS	28570035	LUAD	KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) is the most frequently mutated oncogene in lung adenocarcinoma and a member of the RAS family of GTPases; which also includes HRAS and NRAS.
SMGs within edgetic gains or losses	MET	28373408	NSCLC	In NSCLC; aberrant MET signaling can occur through a number of mechanisms that collectively represent a significant proportion of patients. These include MET or HGF protein overexpression; MET gene amplification; MET gene mutation or fusion/rearrangement; or aberrations in downstream signaling or regulatory components
SMGs within edgetic gains or losses	PIK3CA	23674897	LUAD	PIK3CA mutations H1047R and H1047L are significant genetic alterations in lung adenocarcinoma.
SMGs within edgetic gains or losses	SMARCA4	28555282	NSCLC	SMARCA4-deficient pulmonary adenocarcinoma is emerging as a distinctive; albeit phenotypically heterogeneous molecular subgroup of TTF1-negative NSCLC.
SMGs within edgetic gains or losses	STK11	29764856	LUAD	TP53; STK11; and EGFR mutations predict tumor immune profile and the response to anti-PD-1 in lung adenocarcinoma.
SMGs within edgetic gains or losses	TP53	29764856	LUAD	TP53; STK11; and EGFR mutations predict tumor immune profile and the response to anti-PD-1 in lung adenocarcinoma.

To download a file, either filter the gene of interest or select all the entries and then press the "Download as Excel table" button